Bayer's AskBio to advance gene editing and nonviral delivery with ReCode

10 January 2023

Asklepios BioPharmaceutical, the wholly-owned but independently operated subsidiary of Bayer (BAYN: DE), has signed a multi-year research collaboration and option agreement with ReCode Therapeutics.

California-based ReCode is a privately-held genetic medicines company that Bayer’s venture capital arm has previously invested in.

Under the agreement, the companies will work together to potentially discover precision genetic medicines through the development of a platform for full gene insertion by single vector delivery of gene editing and DNA cargoes.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK